Benzinga · Feb 25, 2026
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $44
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $45 to $44.
AP
NASDAQ · APLS
Apellis Pharmaceuticals, Inc.
Healthcare · Biotechnology
$41.03
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 8:27 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.65B
- P/E ratio
- 117.99
- Dividend yield
- 0.00%
- 52-week range
- $16.83 – $41.14
- Volume
- 68.61M
- Avg. volume
- 2.8M
Price performance
APLS price history
1M range · 0 trading sessions · Daily adjusted prices
APLS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest APLS news
The latest Smart Investors Daily articles mentioning APLS.
Stock researchCompany · Overview
APLS research
Overview
Company profile and research snapshot.
Company profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $31.33
- Implied upside
- —
- Analysts
- 28
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | Equal-Weight | — |
| Apr 2, 2026 | Mizuho | Neutral | — |
| Apr 1, 2026 | Barclays | Equal-Weight | — |
| Apr 1, 2026 | Cantor Fitzgerald | Neutral | — |
| Apr 1, 2026 | JP Morgan | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $21
RBC Capital analyst Lisa Walter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and lowers the price target from $22 to $21.
Benzinga · Feb 25, 2026
Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $18
Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $20 to $18.
Benzinga · Feb 25, 2026
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $48
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $45 to $48.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
